JO3079B1 - ادويه اوليه من البريمدينات لمنع تكاثر فيروس نقص المناعه المكتسبه "الايدز" - Google Patents

ادويه اوليه من البريمدينات لمنع تكاثر فيروس نقص المناعه المكتسبه "الايدز"

Info

Publication number
JO3079B1
JO3079B1 JOP/2001/0062A JOP20010062A JO3079B1 JO 3079 B1 JO3079 B1 JO 3079B1 JO P20010062 A JOP20010062 A JO P20010062A JO 3079 B1 JO3079 B1 JO 3079B1
Authority
JO
Jordan
Prior art keywords
hiv replication
formula
prodruge
replication inhibiting
6alkyl
Prior art date
Application number
JOP/2001/0062A
Other languages
English (en)
Inventor
Paul Adriaan Jan Janssen
Jonge Marc Rene De
Corte Bart Lieven Daniel De
Aken Koen Jeanne Alfons Van
Robert W Kavash
Alain Krief
Michael Joseph Kukla
Lucien Maria Henricus Koymans
Donald William Ludovici
Jan Heeres
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of JO3079B1 publication Critical patent/JO3079B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)

Abstract

الاختراع الحالي يتعلق المركبات ذات الصيغة الكيميائية (I) (A1)(A2)N-R1 و N – اكسيد ملح إضافي مقبول صيدلانيا مجموعه امينية رباعية ومركب منه متشابه ضوئيا في الشكل الفراغي، حيث ان R1 عبارة عن مجموعه الكيل ك 1-6 مستبدلة، كب(=أ) – R8 ، كب(=أ)2 – R8 الكيل ط 7-12 كربونيل، الكيل ك 1-6 اوكسي كربونيل الكيل ك 1-6 كربونيل مستبدل اختياريا، R8 تكون الكيل ك 1-6 اريل1 اوهيت1، (A1)(A2)N- عبارة عن شكل رابطة تكافئية من الصيغة الكيميائية الوسيطة (A1)(A2)N-R1 هي بيريميدين مثبط لتزايد HIV ذات الصيغة 2.
JOP/2001/0062A 2000-05-08 2001-05-07 ادويه اوليه من البريمدينات لمنع تكاثر فيروس نقص المناعه المكتسبه "الايدز" JO3079B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20247100P 2000-05-08 2000-05-08

Publications (1)

Publication Number Publication Date
JO3079B1 true JO3079B1 (ar) 2017-03-15

Family

ID=22749996

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2001/0062A JO3079B1 (ar) 2000-05-08 2001-05-07 ادويه اوليه من البريمدينات لمنع تكاثر فيروس نقص المناعه المكتسبه "الايدز"

Country Status (14)

Country Link
US (2) US7034019B2 (ar)
EP (1) EP1282607B1 (ar)
JP (1) JP4969010B2 (ar)
AR (1) AR035573A1 (ar)
AU (1) AU782948B2 (ar)
CA (1) CA2407754C (ar)
DK (1) DK1282607T3 (ar)
ES (1) ES2559273T3 (ar)
JO (1) JO3079B1 (ar)
MY (1) MY136671A (ar)
PA (1) PA8516501A1 (ar)
SA (1) SA01220305B1 (ar)
TW (1) TWI292395B (ar)
WO (1) WO2001085699A2 (ar)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK287270B6 (sk) * 1998-11-10 2010-05-07 Janssen Pharmaceutica N. V. Derivát pyrimidínu
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
ATE407678T1 (de) * 2001-10-17 2008-09-15 Boehringer Ingelheim Pharma Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
SE0104140D0 (sv) 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
AR039540A1 (es) 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
HRP20050089B1 (hr) 2002-07-29 2015-06-19 Rigel Pharmaceuticals Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti
JP2006508997A (ja) * 2002-11-28 2006-03-16 シエーリング アクチエンゲゼルシャフト Ｃｈｋ−、Ｐｄｋ−およびＡｋｔ−阻害性ピリミジン、それらの製造および薬剤としての使用
MXPA05007485A (es) 2003-01-14 2006-01-30 Arena Pharm Inc Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
WO2005012294A1 (en) 2003-07-30 2005-02-10 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
CA2542522A1 (en) 2003-10-17 2005-05-06 Astrazeneca Ab 4-(pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer
US9132135B2 (en) * 2004-09-24 2015-09-15 University Of Maryland, Baltimore Method of treating organophosphorous poisoning
WO2006036686A2 (en) * 2004-09-24 2006-04-06 University Of Maryland, Baltimore Method of treating organophosphorous poisoning
SI1814878T1 (sl) 2004-11-24 2012-06-29 Rigel Pharmaceuticals Inc Spojine spiro-2,4-pirimidindiamina in njihova uporaba
AU2006206458B2 (en) 2005-01-19 2012-10-25 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US7216803B2 (en) 2005-01-21 2007-05-15 Kingsley Chukwudum Nwosu Biometric delegation and authentication of financial transactions
BRPI0606793A8 (pt) 2005-02-04 2018-03-13 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação e uso do mesmo, métodos para a inibição da atividade de trk, para o tratamento ou profilaxia de câncer e para a produção de um efeito anti-proliferativo em um animal de sangue quente, e, composição farmacêutica
SI1853588T1 (sl) 2005-02-16 2008-10-31 Astrazeneca Ab Kemične spojine
ME01229B (me) * 2005-03-04 2013-06-20 Janssen R& D Ireland 2-(4-cijanofenil)-6-hidroksilaminopirimidini koji inhibiraju hiv
US20080287437A1 (en) 2005-05-16 2008-11-20 Astrazeneca Ab Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors
MX2007014881A (es) * 2005-05-26 2008-02-15 Tibotec Pharm Ltd Procedimiento para preparar 4-(1,6-dihidro-6-oxo-2-pirimidinil) amino benzonitrilo.
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
BRPI0610876B8 (pt) 2005-06-08 2021-05-25 Rigel Pharmaceuticals Inc composto, formulação farmacêutica, e métodos de inibir uma atividade de uma jak cinase, e de inibir uma cascata de transdução de sinal em que jak3 cinase desempenha um papel
JP2009513615A (ja) 2005-10-28 2009-04-02 アストラゼネカ アクチボラグ 癌の治療においてチロシンキナーゼ阻害剤として使用するための４−（３−アミノピラゾール）ピリミジン誘導体
NZ577197A (en) 2006-12-08 2011-02-25 Irm Llc Pyrimidine compounds especially 4-phenylamino-2-arylamino-pyrimidine derivatives and compositions as protein kinase inhibitors
CN101678215B (zh) 2007-04-18 2014-10-01 辉瑞产品公司 用于治疗异常细胞生长的磺酰胺衍生物
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
US8293757B2 (en) 2007-08-22 2012-10-23 Irm Llc 5-(4-(haloalkoxy)phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors
MX353308B (es) 2008-05-21 2018-01-08 Ariad Pharma Inc Derivados fosforosos como inhibidores de cinasa.
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
NZ603525A (en) 2008-06-27 2015-02-27 Celgene Avilomics Res Inc Pyrimidine based compound and uses thereof
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
EP2161259A1 (de) * 2008-09-03 2010-03-10 Bayer CropScience AG 4-Halogenalkylsubstituierte Diaminopyrimidine als Fungizide
US9908884B2 (en) 2009-05-05 2018-03-06 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and methods of treating disorders
US8153790B2 (en) 2009-07-27 2012-04-10 Krizmanic Irena Process for the preparation and purification of etravirine and intermediates thereof
EP2493863B1 (en) * 2009-10-30 2015-02-25 Janssen Pharmaceutica NV Phenoxy-substituted pyrimidines as opioid receptor modulators
MX336875B (es) 2010-08-10 2016-02-04 Celgene Avilomics Res Inc Sal de besilato de un inhibidor de tirosina cinasa de bruton (btk).
EP3323818A1 (en) 2010-09-22 2018-05-23 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP2635284B1 (en) 2010-11-01 2019-12-18 Celgene CAR LLC Heterocyclic compounds and uses thereof
WO2012061303A1 (en) 2010-11-01 2012-05-10 Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof
WO2012064706A1 (en) 2010-11-10 2012-05-18 Avila Therapeutics, Inc. Mutant-selective egfr inhibitors and uses thereof
EP2702044B1 (en) * 2011-04-25 2017-03-22 Hetero Research Foundation Process for rilpivirine
EP2704572B1 (en) 2011-05-04 2015-12-30 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
EP2755959B1 (en) * 2011-09-16 2018-05-16 Hetero Research Foundation Rilpivirine hydrochloride
US9364476B2 (en) 2011-10-28 2016-06-14 Celgene Avilomics Research, Inc. Methods of treating a Bruton's Tyrosine Kinase disease or disorder
CA2866852C (en) 2012-03-15 2020-12-29 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
BR112014022790B1 (pt) 2012-03-15 2022-04-19 Celgene Car Llc Sais de um inibidor de quinase de receptor de fator do crescimento epidermal, composição farmacêutica e usos do mesmo
WO2013169401A1 (en) 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
MX2015009952A (es) 2013-02-08 2015-10-05 Celgene Avilomics Res Inc Inhibidores de cinasas reguladas por señales extracelulares (erk) y sus usos.
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
EP3179858B1 (en) 2014-08-13 2019-05-15 Celgene Car Llc Forms and compositions of an erk inhibitor
PL3242666T3 (pl) 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
BR112017027656B1 (pt) 2015-06-22 2023-12-05 Arena Pharmaceuticals, Inc. Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo
MX2019009841A (es) 2017-02-16 2020-01-30 Arena Pharm Inc Compuestos y metodos para el tratamiento de la colangitis biliar primaria.
CN107778255B (zh) * 2017-11-16 2019-10-25 山东大学 一种二芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法和应用
CA3102136A1 (en) 2018-06-06 2019-12-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
CN111875548A (zh) * 2020-07-16 2020-11-03 山东大学 一种5位芳环取代的二芳基嘧啶类衍生物及其制备方法与应用
CN112546969B (zh) * 2020-12-07 2022-12-23 安徽贝克制药股份有限公司 催化加氢连续生产装置和利托那韦中间体的制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2748122A (en) * 1954-05-06 1956-05-29 Searle & Co 2-anilino-4, 6-dimethylpyrimidines
DD236667A1 (de) * 1984-05-21 1986-06-18 Fahlberg List Veb Fungizide mittel, die 2-amino-pyrimidine enthalten
JPH0784445B2 (ja) * 1986-12-03 1995-09-13 クミアイ化学工業株式会社 ピリミジン誘導体および農園芸用殺菌剤
JPH02308248A (ja) 1989-05-24 1990-12-21 Fuji Photo Film Co Ltd アミノピリミジン系色素形成カプラーおよび該カプラーを含有するハロゲン化銀カラー写真感光材料
GB9012592D0 (en) * 1990-06-06 1990-07-25 Smithkline Beecham Intercredit Compounds
GB9013349D0 (en) 1990-06-14 1990-10-17 Marconi Gec Ltd Transponder system
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
WO1995010506A1 (en) 1993-10-12 1995-04-20 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
TW530047B (en) * 1994-06-08 2003-05-01 Pfizer Corticotropin releasing factor antagonists
US5834687A (en) 1995-06-07 1998-11-10 Acuson Corporation Coupling of acoustic window and lens for medical ultrasound transducers
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
CN1163401A (zh) 1996-02-13 1997-10-29 李占元 全自动血球计数仪试剂及配制方法
NO311614B1 (no) 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
GB9705361D0 (en) * 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
EP1054004B1 (en) * 1997-12-15 2008-07-16 Astellas Pharma Inc. Novel pyrimidine-5-carboxamide derivatives
EA200000840A1 (ru) 1998-02-17 2001-02-26 Туларик, Инк. Антивирусные производные пиримидина
EA002973B1 (ru) 1998-03-27 2002-12-26 Янссен Фармацевтика Н.В. Производные пиримидина в качестве ингибиторов репликации вируса иммунодефицита человека
EP0945447A1 (en) 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
SK287270B6 (sk) * 1998-11-10 2010-05-07 Janssen Pharmaceutica N. V. Derivát pyrimidínu
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds

Also Published As

Publication number Publication date
AR035573A1 (es) 2004-06-16
JP2003532713A (ja) 2003-11-05
ES2559273T3 (es) 2016-02-11
US20030186990A1 (en) 2003-10-02
TWI292395B (en) 2008-01-11
JP4969010B2 (ja) 2012-07-04
PA8516501A1 (es) 2002-08-26
SA01220305B1 (ar) 2007-03-10
WO2001085699A3 (en) 2002-02-28
CA2407754A1 (en) 2001-11-15
DK1282607T3 (en) 2016-02-01
EP1282607B1 (en) 2015-11-11
CA2407754C (en) 2009-09-15
US7763631B2 (en) 2010-07-27
US20060009474A1 (en) 2006-01-12
WO2001085699A2 (en) 2001-11-15
AU782948B2 (en) 2005-09-15
AU6027701A (en) 2001-11-20
MY136671A (en) 2008-11-28
EP1282607A2 (en) 2003-02-12
US7034019B2 (en) 2006-04-25

Similar Documents

Publication Publication Date Title
JO3079B1 (ar) ادويه اوليه من البريمدينات لمنع تكاثر فيروس نقص المناعه المكتسبه "الايدز"
WO2002024650A3 (en) Pyridinone and pyridinethione derivatives having hiv inhibiting properties
MY121108A (en) Hiv replication inhibiting pyrimidines.
MXPA04001320A (es) Antranilamidas artropodicidas.
MXPA02012314A (es) Compuestos de 1,2-dihidropiridina, metodo de fabricacion y utilizacion de los mismos.
MXPA05008364A (es) Derivados de pirimidina para la prevencion de una infeccion por vih.
TR200201057T2 (tr) P38 protein kinazı inhibitörleri olarak heteroalkilamino ikameli bisiklik nitrojen heterosaykılları.
MY138097A (en) Insecticidal anthranilamides
ATE247107T1 (de) Angiotensin-ii-antagonisten
DK0539086T3 (da) Kondenserede pyrimidinderivater og deres anvendelse som angiotensin II-antagonister
BG106116A (en) 5-cyano-2-aminopyrimidine derivatives
NO20020823D0 (no) Heterosykliske forbindelser og deres anvendelse som metabotrofisk glutamatreseptor-antagonister
BR9907104A (pt) Compostos de 4-(2-ceto-1-benzimidazolinil)piperidina como agonistas do receptor orl1
EP1020462A4 (en) HETEROCYCLIC COMPOUNDS AND ANTITUMOR AGENT CONTAINING SAID COMPOUNDS USED AS ACTIVE INGREDIENTS
AU2001230564A1 (en) Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
NO20021503L (no) Kinazolinoner
MY130950A (en) 4-(1h-indol-1-yl)-1-piperidinyl derivatives
DK0975222T3 (da) Befugtelig eller vandoplöselig granulær agrokemisk sammensætning
PA8533501A1 (es) Derivados de pirimidina 2,4,5-trisustituida
MEP17408A (en) N-(heterocyclyl)benzene or pyridine sulphonamides as antithrombotic agents and anticoagulants
MXPA03000887A (es) Derivados heterociclicos fusionados como inhibidores de fosfodiesterasa.
BG105419A (en) 2,4-disubstituted triazine derivatives
ATE108447T1 (de) Sulfonylharnstoffe als herbizide.
MXPA01008308A (es) Proceso para la preparacion de compuestos de 6-(perfluoroalquil) uracilo.
MX2007005892A (es) Derivados de acido piridonacarboxilico novedosos y sales de los mismos.